Manhattan Completes Merger Transaction With Ariston
Under the terms of the merger agreement, Manhattan, upon the closing, issued 7.06 million shares of its common stock to Ariston stockholders and debt holders (which represents approximately 6 percent of Manhattan Pharmaceuticals common stock on an issued and outstanding basis).
Under the terms of the merger agreement, Manhattan could issue up to an additional 24.74 million shares upon completion of certain development milestones relating to the Ariston product candidates. If all the product development milestones are reached, former Ariston stockholders and debt holders will own 22 percent of Manhattan common stock on a currently issued and outstanding basis.
In addition, Manhattan has reserved 43.63 million shares of its common stock for the possible future conversion of $16.45m of Ariston's outstanding convertible debt. The debt holders have no recourse to Manhattan for repayment. They do have the right to convert their notes into shares of Manhattan common stock.
In connection with the Ariston transaction, Manhattan will appoint Malcolm Morville, formerly president and CEO of Ariston, as executive chairman of Manhattan Pharmaceuticals. Michael McGuinness will remain Manhattan Pharmaceuticals' COO and CFO and Mary Spellman, will also continue to serve as head of dermatology and drug development. Michelle Carroll will serve as vice president for corporate development.
With the completion of the Ariston transaction, Manhattan's pipeline has been expanded from two to four product candidates: Hedrin, AST-726, AST-915 and GEL.
Is this a sensible move from Manhattan?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.